Lipocine reported second-quarter 2026 revenue of $190,099. This represents a sharp decline from $622,849 in the prior-year period. The drop resulted from the absence of a one-time $500,000 license fee recognized in 2025.
Net loss for the quarter widened to $2.6 million. This compares to a $2.2 million loss a year earlier. Loss per share reached ($0.32), compared to ($0.41) in the second quarter of 2025.
Lead candidate LPCN 1154 failed to meet its primary endpoint in a Phase 3 trial for postpartum depression. Lipocine has initiated a new clinical trial for the candidate. The company scheduled a guidance meeting with the FDA for Q3 2026 to determine the drug's future development path.